This story was originally published May 4.

Sequenom said last week that it is planning to increase multiplexing and automate sample prep for its MaterniT21 Plus test during the second half of the year, which will double its yearly capacity to 200,000 tests.

Additionally, it reported during a conference call to discuss its first-quarter earnings that the uptake of MaterniT21 Plus has been increasing weekly, and as of the last week of April, its accession run rate was more than 45,000 tests per year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.